Institut de Cancérologie de l'Ouest - site de Saint Herblain — Clinical Trial Site

9 Registered trials

2 Currently recruiting

Organisation

Institut de Cancérologie de l'Ouest - site de Saint Herblain

Location

SAINT HERBLAIN, France

Identifier

ORL-000004834

Address

Boulevard Jacques Monod, 44805, France

Departments

Medical Oncology
Medical oncology department
ONCOLOGIE
Oncologie Médicale
Oncology
Unité de Développement des Thérapeutiques Précoces (UDTP)

Clinical trials at this site (9)

Search interface

SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast C… Recruiting

2023-505923-30-00 Patients with hormone-receptor positive (HR+) and human 4 2021-05-11
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL C… Ended

2024-514032-25-00 Patients with a histilogically confirmed diagnosis of c 4 2024-12-11
PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first… Ended

2024-518553-41-00 colon cancer and rectal with liver metastasis 5 2024-11-08
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Ended

2024-513455-33-00 Bone sarcoma 4 2014-09-11
EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer Ended

2023-509336-25-00 Metastatic castration-resistant prostate cancer 9 2024-06-12
A phase I of TG6050 in the treatment of patients with metastatic lung cancer Ended

2024-513093-22-00 Non-small cell lung cancer (NSCLC) 1 2023-03-27
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer Ended

2023-506922-35-00 Locally Advanced or Metastatic Solid Tumors with EGFR a 1 2022-01-24